Evolus, Inc. (NASDAQ: EOLS ) Q4 2024 Earnings Conference Call:
On March 4, 2025, at 4:30 PM ET, Evolus, Inc. (NASDAQ: EOLS ), a leading medical technology company focused on the development and commercialization of neurotoxins for various aesthetic applications, held its Q4 2024 earnings conference call. The call was hosted by Nareg Sagherian, VP and Head of Global IR and Corporate Communications, and featured presentations from David Moatazedi, President and CEO, Rui Avelar, Chief Medical Officer and Head of R&D, and Sandra Beaver, CFO.
Company Participants:
- Nareg Sagherian – VP and Head of Global IR and Corporate Communications
- David Moatazedi – President and CEO
- Rui Avelar – Chief Medical Officer and Head of R&D
- Sandra Beaver – CFO
Conference Call Participants:
- Annabel Samimy – Stifel
- Gangireddy Madhumitha – Stryker
- Navann Ty – BNP Paribas
- Doug Tsao – H.C. Wainwright
- Serge Belanger – Needham & Company
During the call, Evolus executives discussed the company’s financial results, business updates, and future growth plans. Here are some key highlights:
Financial Results:
Evolus reported Q4 2024 revenue of $125.3 million, up 15% YoY, driven by strong sales of Jeuveau, its FDA-approved neurotoxin for aesthetic indications. The company’s net loss for the quarter was $10.5 million, compared to a net loss of $11.8 million in the same period last year. Evolus’s full-year 2024 revenue came in at $416.9 million, up 23% YoY.
Business Updates:
Evolus announced that it has filed a supplemental Biologics License Application (sBLA) with the FDA for Jeuveau for the treatment of glabellar lines in adults. The company also shared that it is expanding its sales force to support the growth of Jeuveau and increase market penetration. Additionally, Evolus provided an update on its pipeline, including DWP-450, a potential neurotoxin for the treatment of dystonia, which is in Phase 2 clinical trials.
Future Growth Plans:
David Moatazedi, President and CEO, expressed his confidence in Jeuveau’s continued growth, stating, “We believe Jeuveau’s unique value proposition, which includes its competitive pricing, faster onset, and longer duration, will continue to resonate with both healthcare providers and consumers.” The company also plans to invest in research and development to expand its product portfolio and maintain its competitive edge.
Now, let’s discuss how Evolus’s Q4 2024 earnings and future plans will impact you and the world:
Impact on Individuals:
If you are an investor in Evolus, the company’s strong financial performance and growth plans are positive signs. Evolus’s revenue growth and expanding product pipeline could lead to increased stock value and potential returns on investment. Additionally, as a consumer, the availability of more affordable neurotoxin options, like Jeuveau, can make aesthetic treatments more accessible.
Impact on the World:
From a global perspective, Evolus’s success in the neurotoxin market could lead to increased competition and innovation in the industry. This competition could result in more affordable and effective treatment options for consumers, as well as potential advancements in neurotoxin technology and applications. Furthermore, Evolus’s expansion into new markets, such as Asia, could contribute to the global growth of the aesthetic industry.
Conclusion:
Evolus, Inc.’s Q4 2024 earnings call provided investors and stakeholders with valuable insights into the company’s financial performance, business updates, and future growth plans. With strong revenue growth, a promising pipeline, and a focus on innovation and affordability, Evolus is well-positioned to continue its success in the neurotoxin market. Additionally, the company’s potential impact on individuals and the world, through increased access to affordable aesthetic treatments and potential advancements in neurotoxin technology, underscores the importance of Evolus’s role in the healthcare industry. Stay tuned for future updates and developments from Evolus.
